MEI Pharma (LTS:0JW9) Other Stockholders Equity : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MEI Pharma Other Stockholders Equity?

MEI Pharma's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $0.00 Mil.

MEI Pharma's quarterly Other Stockholders Equity declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

MEI Pharma's annual Other Stockholders Equity increased from Jun. 2022 ($-0.00 Mil) to Jun. 2023 ($0.00 Mil) but then declined from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($0.00 Mil).

MEI Pharma Other Stockholders Equity Historical Data

The historical data trend for MEI Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Other Stockholders Equity Chart

MEI Pharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Stockholders Equity

Get a 7-Day Free Trial

MEI Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

MEI Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

MEI Pharma Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (LTS:0JW9) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

MEIP:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma Headlines

No Headlines